Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery of THCA Cannabinoid’s Neuroprotective Treatment Potential
September 20, 2017 07:00 ET
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF), a Canadian licensed medical producer of cannabis, is pleased to report...
Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
August 24, 2017 16:16 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine)...
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
August 08, 2017 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
June 26, 2017 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights
May 09, 2017 16:10 ET
|
Voyager Therapeutics
VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from Cohort 3...
Taconic Biosciences Announces Release of New Parkinson’s Disease Animal Model
April 25, 2017 12:54 ET
|
Taconic Biosciences
HUDSON, N.Y., April 25, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced that effective April 17, 2017, in...
Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
April 25, 2017 07:02 ET
|
Voyager Therapeutics
Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...
Study: More Brain Training is Better for Parkinson’s Patients
February 27, 2017 08:00 ET
|
Posit Science
SAN FRANCISCO, Feb. 27, 2017 (GLOBE NEWSWIRE) -- A study published online (ahead of print) in the International Journal of Neuroscience indicates that “more is better,” when it comes to brain...
Voyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
January 20, 2017 07:31 ET
|
Voyager Therapeutics
Cohort 3 Enrollment Complete with Increased Coverage of the Putamen Observed Cohort 3 On Track for Six-Month Data Update Mid-2017 CAMBRIDGE, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Voyager...
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
December 07, 2016 16:05 ET
|
Voyager Therapeutics
VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was well-tolerated Program on track to report...